.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
UBS
Harvard Business School
Federal Trade Commission
Mallinckrodt
Cerilliant
Moodys
Medtronic
US Army
Fish and Richardson

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021813

« Back to Dashboard
NDA 021813 describes ELESTRIN, which is a drug marketed by Mylan Speciality Lp and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug. Additional details are available on the ELESTRIN profile page.

The generic ingredient in ELESTRIN is estradiol. There are seventy-five drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the estradiol profile page.

Summary for 021813

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:2
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
Formulation / Manufacturing:see details

Pharmacology for NDA: 021813

Ingredient-typeEstradiol Congeners
Mechanism of ActionEstrogen Receptor Agonists

Medical Subject Heading (MeSH) Categories for 021813

Suppliers and Packaging for NDA: 021813

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ELESTRIN
estradiol
GEL, METERED;TRANSDERMAL 021813 NDA Meda Pharmaceuticals 0037-4801 0037-4801-35 1 BOTTLE, PUMP in 1 CARTON (0037-4801-35) > 35 g in 1 BOTTLE, PUMP
ELESTRIN
estradiol
GEL, METERED;TRANSDERMAL 021813 NDA Meda Pharmaceuticals 0037-4801 0037-4801-70 2 BOTTLE, PUMP in 1 CARTON (0037-4801-70) > 35 g in 1 BOTTLE, PUMP

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:GEL, METERED;TRANSDERMALStrength0.06% (0.87GM/ACTIVATION)
Approval Date:Dec 15, 2006TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jun 25, 2022Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Aug 3, 2021Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Express Scripts
Fish and Richardson
Harvard Business School
Federal Trade Commission
Fuji
Mallinckrodt
Dow
Novartis
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot